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Safety of bioabsorbable implants in vitro
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Abstract
Background: The aim of the present study was to investigate the safety of bioabsorbable plates and screws in
humans.
Methods: For this purpose, an implant system based on [poly(lactic-co-glycolic acids)(85:15)] was designed. The
system was tested for pH, temperature, and swelling and then its surface morphology was analyzed for surface
porosity using environmental electron microscopy. Then, the effects of this bioabsorbable system on the viability
and profileration of osteocytes were examined on a molecular level via in vitro experiments. A [poly(lactic-co-glycolic
acids)(90:10)] bioabsorbable implant, which is commercially available and used in orthopedic surgery, was used as
control group. For the statistical evaluation of the data obtained in the present study, the groups were compared by
Tukey HSD test following ANOVA. The significance level was set as p < 0.05.
Results: It was observed that the osteocytes cultivated on the PLGA system designed in the present study included
more live cells and allowed more proliferation compared to the control.
Conclusion: One of the criteria in the selection of implants for orthopedic surgery is that a good implant should not
need removal and thus a second surgery. In the present study, a bioabsorbable implant was designed considering this
criterion. The present study is the first step to prove the safety of this new design by in vitro toxicity and viability
experiments.
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Background
Regarding the use of implants in orthopedic trauma surger-
ies, the followings are expected: stabilized fixation, minimal
surface contact, and causing no foreign body reaction or tox-
icity. To avoid the extraction of an implant by a subsequent
surgery for any reason, bioabsorbable implants have recently
been gaining popularity [1–3].
The modern implants used in orthopedic surgeries
help bone fixation morphologically, but the resorption
on the surface has been one of the problems remaining
unsolved [1, 2, 4].
Removal of an orthopedic implant requires surgery,
which is not a desired process. The development of an
innovative implant that can dissolve and be biologically
absorbed after it is no longer needed has always been
considered [2–5].
In the present study, bioabsorbable [poly(lactic-co-
glycolic acids)(85:15)] (PLGA) composites were prototyped
based on chitosan and imitating the combined plate and
screw implant system. The biocompatibility of this implant
was evaluated via an in vitro experimentation on osteocytes
showing osteoblastic activity in order to determine whether
it can be used in humans.
Methods
This study was conducted with the permission of the Local
Ethics Evaluation Commission of Medipol University,
Medical Faculty. Signed informed consent forms were
obtained from the participants to conduct research on
tissues.
Materials
Collagenase Type II enzyme (1 mg/mL; Invitrogen
Corporation, USA), Hank’s Balanced Salt Solution 1X,
14025, Gibco (HBSS), RPMI–1640 (Sigma-Aldrich GmbH,
Germany), DMEM (1000 mg glucose/L, Sigma Chemical
St. Louis, USA) Penicillin-Streptomycin, fetal bovine serum
(Sigma Chemical St. Louis, USA), Osteoblast Stimulator
MesenCult-XF kit (MSC Basal Medium human-05431,
Osteogenic Stimulatory Supplement human-05435,
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and β-Glycerophosphate human-05436), which is used
as osteogenic progenitor, were obtained from Stemcell
Technology, USA (≠9966/05434).
The laminar flow cabinet (Air Flow-NUVE/NF–800 R)
and the incubator (NUVE) were obtained from Akyurt,
Ankara, Turkey. Primary cell culture consumables (flask, 6-
well plate, pipette, tube, and scraper) were obtained from
Sarstedt, Greigner. A CKX41 invert microscope, and for
ELISA measurements, a Mindray MR 96 A were used
(PRC). A Quanta 250 FEG (Fei Company, Hillsboro, Oregon,
USA) environmental scanning electron microscope (ESEM)
was used. For porosity assessment of the plates and surface
morphology characterizations, a FEI-Philips XL30 ESEM-
FEG scanning electron microscope and gold-plated Polaron
SC7640 Sputter Coater were used. The antibodies used for
immune phenotyping were BD brand and they were ana-
lyzed using a BD FACS-Calibur flow cytometer.
Experiment design
All experiments were performed three times. Primary
osteocyte cultures, which were used for viability, profi-
leration and toxicity experiments, were prepared fresh
and replaced every other day.
The PLGA implant system was designed as prototype.
Bioabsorbable [poly(lactic-co-glycolic acids)(90:10)] Lac-
tasorb® implant, which is commercially available and can
be used in orthopedic surgery, was used as control.
Standard primary osteoblast cultures were obtained from
the patients’ bone tissues (n = 6). Samples were prepared
in sufficient numbers on days 1, 7, 14, and 21 for MTT-
ELISA, energy-dispersive X-ray spectroscopy (EDS)
microanalysis, SEM, and ESEM analyses (Fig. 1).
Preparation of the PLGA-based plate and screw implant
system and its placement in well-plates
Before the preparation of the prototype, that were imi-
tating the PLGA plate and screw, polyethylene glycol
300 (PEG), hydroxyapatite (HA) and chitosan were
dissolved in proper solvents. Then, using an assay bal-
ance, PLGA was prepared on a watch glass dish with a
85:15 lactide:glycolide ratio. PLGA beads placed in fal-
con tubes with %4 pure acetone (−CH3COO−) solution
to have %6 concentration.
The solutions were vortexed three times for 1 min
each during the 2-h waiting period, and then the solutions
were taken into a porcelain beaker and kept in a hot water
bath for 25 min keeping the temp below 50 °C. Ammo-
nium thiosulfate was added to the solution (11 g/55 ml)
made with chitosan in bovine serum and HCl (0.01 M). It
was stirred using a glass rod. The hardness of the product
was adjusted by the addition of poly(vinyl alcohol), chito-
san, and ammonium thiosulfate, in this order, as cross
linker. To obtain the hardness level that is suitable to be
used in surgery, this process was repeated several times.
The samples to be used in well-plates were retrieved
from the solvents using a vacuum desiccator at 38 °C.
The samples were washed in sterile PBS and distilled
water, and then dried by freezing. The samples were
then sterilized in ethylene oxide.
Analyses of the temperature, pH and swelling tests of the
PLGA prototype designed
For the assessment of the swelling behaviors of the
plates, the Flory Rehner theory was used [6, 7]. For this
purpose, samples were cut into pieces with a 9-mm
diameter and 2-mm height. These samples were put in
beakers with phosphate buffer (at 37 °C, pH, 7.4). The
samples were dried using blotting paper several times in
the 21-day waiting period and they were weighted. Hy-
dration rates were calculated using the data obtained in
this period [8].
To obtain the swelling curves of the plates, the data
obtained gravimetrically by the Swelling rate = (Wt-W0)/
W0 equation were plotted against time (W0 = Dry weight
of the sample, Wt =Wet weight of the sample at time t).
Fig. 1 Experimental study design
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The plates were placed in hot water baths at 25 °C and
50 °C and the diameter changes were measured by an
electronic calipers and the data were plotted. The diam-
eter changes in PBS solutions with different pH values
(6, 6.5, 7, 7.4, 7.5, 8) at 37 °C were measured and re-
corded [9–11].
Obtaining the primary osteoblasts
The patients (n = 6, mean age = 64) included in the
present study were diagnosed with severe osteoarthritis
based on Kellgren and Lawrence Scale [12] and who did
not respond to medical and conservative treatment pro-
tocols. Bone tissues obtained from these patients who
underwent total knee arthroplasty were used to prepare
the primary osteocyte cultures (Fig. 2).
These tissue parts were transferred in DMEM contain-
ing %5 penicillin. They were transferred to the labora-
tory at 4 °C in proper conditions. The bone tissue cells
taken into the flow cabinet were irrigated in PBS solu-
tion and red blood cells were separated by minisart fil-
ters. The bone tissues divided into 0.3 cm3 pieces were
washed with 0.1 % (a/h) HBSS solution. The samples
were taken into tubes per the manufacturer’s instruc-
tions and 400 μg Clostridium Histolyticum-based colla-
genase type II enzyme dissolved in HBSS solution was
added. The samples were kept in an incubator with 5 %
CO2 and at 37.4 °C for a day and they were centrifuged
at 4 °C and 1300 rpm for 15 min. The cell pellets depos-
ited at the bottom were resuspended using the culture
medium prepared with RPMI-1640. They were left for
incubation after transferred to flasks.
Until the third passage, the medium of the cells were
replaced every other day with the following culture con-
tent: FBS, Penicillin-Streptomycin, and RPMI-1640.
Osteogenic stimulator kit was used for the osteoblastic
activity to occur. Following the second passage, for
16 days, the medium of the cells were replaced every other
4 days with the following culture content: 47.5 ml MSC
Basal Medium, 2.5 ml Osteogenic Stimulator Supplement,
and 1 Molar 175 microliter β-Glycerophosphate, FBS,
Penicillin - Streptomycin, DMEM.
The cells attaining to minimum 90 % confluency, ad-
hering to the bottom, and with completed immunoflow
cytometric analyses were taken for experimentation.
Then, the samples were placed in well pates (65X103
cells/well) by counting on Thoma lams with trypan blue.
Invert light microscopy images
Microphotographs of the cell organizations were taken
at 4X, 10X, 20X and 40X zoom levels before they were
placed into cell plates using an invert light microscope.
The images were assessed using Olympus cell softima-
ging System software.
ESEM and SEM analyses
Culture medium in the well plates were discarded. For
the fixation of the cells, 2.5 % glutaraldehyde solution
containing 97.5 ml cacodylate buffer and 2.5 ml glutaral-
dehyde was added to the wells to cover the samples. The
glutaraldehyde solution was removed off the samples
with a pipettor gun after 2 hours of waiting period at
room temperature. The samples were washed with caco-
dylate buffer 3 times. The samples were covered again
with cacodylate buffer after the last wash and kept at 4 °C
in a refrigerator until measurement.
The cells in the control group were directly evaluated
with ESEM microscope, and the cells placed on plates
were coated with gold and evaluated with SEM. The
samples were cooled down to −20 °C to perform these
analyses. They were dried by holding the samples over-
night in a Freeze-dryer, [6, 13–16]. Then, the samples
were coated with 5 nm gold. Images were taken at vari-
ous zoom levels while working at 10 kV.
Fig. 2 Osteochondral tissue obtained during total knee replacement surgery
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Energy-dispersive X-ray spectroscopy (EDS) microanalysis
In the analysis method that is used for elemental analysis
or chemical identification, the surface of the sample is
bombarded with high-energy electrons. Following this
collision, due to the electron discharge, the movement
of electrons from the outer orbitals to the inner ones to
fill in gaps is activated to make the chemical structure
stable again. In the meantime, the chemical sample that
lost energy reflects this energy loss by emitting X-ray. The
energy and wavelength of this X-ray is not only related with
the atom but also a characteristic feature of the orbitals
with which the atom is exchanging electrons [15, 16].
X-rays originated from the chemical samples are de-
tected by the semi-conductor detector. The electrons
passed onto the conductivity band convert to electricity
signals.
By only selecting the X-ray peaks of the respective
element and by counting the X-rays via the EDS de-
tector, for each point on the sample surface, the relative
ratio of the element on the surface of the sample can be
determined. The 2-dimensional map of these measure-
ments show the X-ray map of the element of the chem-
ical [15, 16].
To this end, chemical stability of the implants was
assessed by carbon, hydrogen, and nitrogen percentages
in the compounds of the control group and the PLGA
prototype. By this way, whether the new implant system
hosts the live cells as well as the commercially available
counterparts was also evaluated.
Immunophenotyping by flow cytometry
Before passaging (phase 4), the general condition of the
cells cultured in DMEM medium with dexamethasone
(100 nM), 05 μM ascorbate-2-phosphate, and 10 mM
beta glycerophosphate was assessed by invert micros-
copy and reported. The osteoblasts adhering to the sur-
face were scraped with 0.25 % Trypsin - EDTA and a
scraper, and transferred to tubes. They were centrifuged
twice at 4 °C and 2000 rpm for 5 minute each. Superna-
tants in the 15-cc falcon tubes were discarded. The pel-
lets on the bottom were resuspended with the cell
culture medium content. The cells were counted and
0.5X105 cells were incubated in each well (at 22.4 °C, in
a dark environment, for 20 min) with fluorescein iso-
thiocyanate (FITC)-phycoerythrin (PE) that is specific to
surface markers, conjugated monoclonal antibodies
(HLA-DR, CD34, CD45, CD117 and CD44), and proper
isotype controls.
At the end of the time period, the medium content
was cleared from artifacts by centrifuging at 4 °C and
1300 rpm with the addition of pH = 7.4 PBS including
0.1 % sodium azide. The resuspended cell suspensions
were evaluated using the flow cytometry device. The
data were analyzed with BD Cell Quest Software (Safe
Net Sentinel-CQPro-SRB) and the images were reported.
Determination of viability and toxicity effects: MTT-ELISA
analyses
Viability tests were carried out using the commercially
available MTT kit per the manufacturer’s instructions.
The working principle of the test is that tetrazolium
rings in live cells are crashed by the dehydrogenase en-
zymes found in the mitochondria, which forms blue-
colored formazan crystals, and it does not occur in dead
cells. One extra well from each cell group and the control
was set aside for this analysis. In a dark environment, on
days 1, 7, 14, and 21, the medium in each of the well was
discarded using a pipette gun. In each well, 500 μl culture
medium solution containing MTT (3-[4,5- dimethylthiazol
−2-yl]-2,5-diphenyltetrazolium bromide) and DMEM (1:6)
was placed and they were incubated for 3 days. At the end
of this time period, to end the reaction, 25 μl 10 % SDS was
added into each well.
200 μl MTT solutions were extracted and transferred
to 96-well plates. Then the samples were analyzed using
the ELISA device at 490 nm and the results were
reported.
This test was used to check whether the cells survive
and maintain healthy proliferation in the PLGA proto-
type compared to the control group.
The proliferation of the cell cultures grown in the de-
signed implant was calculated as percentage (%) using
the following equation:
Proliferation was assumed to be 100 % in the control
group on day 1, which was taken as baseline. Live cell
numbers were also reported for days 1, 7, 14, and 21 as
percentage (%) and the differences between the PLGA
prototype and the control group were investigated.
Statistical analysis
In the analysis of the data, results were considered in
terms of cell proliferation. The results were expressed as
mean ± standard deviation. Minitab 16 was used for stat-
istical analysis. One-way ANOVA test was used for
inter-group comparisons. To test the significance of any
meaningful relationship, Tukey HSD test was used.
Alpha significance level was set as <0.05.
Results
An evaluation of the temperature, pH, and swelling test
results of the PLGA prototypes
Temperature and pH analyses showed the degradation
of the PLGA implant in PBS and different pH levels
(Fig. 3).
pH change indicates that the PLGA-based plate sam-
ples have a high buffering capacity.
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Fig. 3 Evaluation of the temperature, pH, and swelling test results of novel designed PLGA composites
Fig. 4 Microphotographs of the cell organizations were taken at 4X, 10X, 20X and 40X zoom levels before they were placed into cell plates using
an invert light microscope
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Invert light microscopy evaluation
Before the subculturing that is required for immunophe-
notyping, invert microscope images of the osteocytes
showed that they were healthy in 90 %;15/16 confluent
ratio (Fig. 4).
Evaluation of the surface morphologies (with and
without cells) of the designed PLGA by SEM and the
cells by ESEM
The morphological evaluation of the surface and cross-
sectional structure of the plates and the SEM analysis
(to inquire about the cellular nesting) showed large
pores inside the plates (Fig. 5).
In the PLGA prototype, on figure the number and
distribution of cells in the cracks that occurred after
the dry off were regular and homogeneous compared
to the control group. Besides, the density and exten-
sion of the extracellular matrix covering the PLGA
were noteworthy on day 21.
EDS test results, which was performed after the scan-
ning electron microscopy, showed dense, cubical, shiny
calcium zones (Fig. 6).
EDS analysis of the samples with no cells showed that
the PLGA implant system contained more carbon atoms
(an indication of chemical stability) and more oxygen
atoms allowing more oxygen transmission (an indication
of a better growth medium for cells) compared to the
control group (Table 1).
EDS analysis of samples which include cellss how ed
that, PLGA prototype is a good host. Azote atom rate,
which is the indicator of cell viability, was 19.70 % in
the PLGA group. Novel design PLGA permitted beter
osteoblast proliferation.
Assessment of the immunophenotyping by flow
cytometry
In addition to MTS ELISA analyses, the osteoblastic ac-
tivity specific to bones was proven by proliferation and
differentiation flow cytometry analysis by the help of
fluorescein isothiocyanate (FITC) - phycoerythrin (PE),
that is specific to cell surface markers, conjugated mono-
clonal antibodies ( HLA-DR, CD34, CD45, CD117 and
CD44), and proper isotype controls. It was observed that
MTS-ELISA results were in line with flow cytometry re-
sults (Table 2).
Following the third phase subculture of the cells iso-
lated from human primary osteocyte and osteoblasts,
HLA-DR, CD34, CD117 and CD45 markers showed
negative expression and CD 44 marker showed positive
expression.
Statistical evaluation of viability, proliferation, and
toxicity by MTT-ELISA
In the evaluations regarding the cell proliferation, as the
cell viability was reported on days 1, 7, 14 and 21 as
Fig. 5 Morphological evaluation of osteocytes on the control and novel designed PLGA groups. a: ESEM images of cells before seeding into
cntrol group and novel design implant group. b: SEM images of 7 days. c: SEM images of 14 days. d: SEM images of 21 days
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percentage (%), which group showed the best osteo-
blastic activity and growth was reported (Fig. 7).
Discussion
Recently, application of the polymeric biological systems
gained increased popularity [17]. Current literature
showed that, metal implant systems are considered as
the first choice in the treatment protocols due to their
mechanical strength but they may exert toxic effects on
the viable cells in the host by inflammation and depos-
ition of metabolites secondary to the hydrolysis of the
metallic materials [18].
The choice of the type of material that should be used
in trauma patients recently became more important due
to the possible positive and negative impact of the ma-
terial on both the well being of the host and the bone re-
modelling. Biomaterals seems to be advantageous for the
patients because they do not necessitate another oper-
ation for extraction and they may permit bone formation
in the site of elution.
Biomaterial design history in the literature shows that
the use of some materials, such as calcium phosphate, was
investigated because it was hypothesized that they may
simulate theosteogenesis, but it was observed that they do
not induce the bone development but they are suitable for
hard tissue formation [19]. Tricalcium phosphate-beta-
based implant systems were used, no regeneration was re-
ported in trials and they formed connective tissue capsules
[20, 21]. In addition, hydroxyapatite (HA)- coated screws
were reported to be used successfully [22].
Therefore, in the preparation of the PLGA-based im-
plant system in the present study, HA was used to make
the composite instead of tricalcium phosphate-beta. To
increase the porous features of the tissue scaffold made
with hydrophobic polymers, it was reported that water is
added to the polymer solutions [23, 24].
In the present study, for the preparation of the
polymer prototype, after freezing at −80 C for
48 hours, the material was dried. The water added to
the solution later was removed to obtain a more
stable surface area.
In the literature, in the design of such biomaterial sys-
tems, osteoinductive and osteoconductive materials,
such as HA and chitosan, have been used. By this way,
bone and capillary network formation is allowed yielding
a 3-dimensional structure boosting cell proliferation,
which has been thought to be a proper option for the
treatment of bone fractures [25–28].
Therefore, in the present study, in addition to PLGA,
which has osteoconductive featuresprotecting the osteo-
blasts or the cells that my convert to osteoblasts, HA
and chitosan were usedin the making of the implant pro-
totype.Before the use of any new design in humans, indi-
vidual chemicals involved in the design or theentire
compound is assessed in culture medium, and partial
atypical cell development may causechanges in the cell
culture content, which may result in cell loss [29].
As it is well known, PEG's are frequently used in a
number of medical procedures (designation of surface
active materials and etc.) to provide polymerization and
preferred due to their high biocompatibility [30, 31].
However, we did not use PEG 300 ( a PEG derivative )
in an attempt to design a surface active agent - as you
indicated. We used is as an adjunct binding materials to
promote polymerization of the designed PLGA and con-
solidate the weak crosslinking that occured with chito-
san (provision of increased binding by increasing the
hydrophilic regions). PEG 300 used in our design is 1/50
mole/mole and it is usually neglected hence it is in trace
amounts.
Even though the fact that in vitro experimental ana-
lyses in the present study were performed in culture
medium may be considered as a limitation of the study,
the cells used here are primary cell cultures obtained
from human bone tissues, not from cell-line or animal
tissues, whichmakes the data more robust. The actual
limitation of the study was the lack of biomechanical
tests of the implant. However, in this first pilot study, in
Table 1 Energy-dispersive X-ray spectroscopy (EDS) microanalysis
Quantification
Element (Wt %) Controlgroupwithcells A noveldesignPLGA
groupwithcells
C K 17.64 24.87
N K 13.11 19.70
O K 26.74 26.67
Na K 10.13 6.54
Mg K 16.13 4.63
P K 6.56 5.65
Ca K 9.69 11.94
TOTAL 100 100
C: Carbon, N: Azote, O: Oxygen, Na: Sodium, Mg: Magnesium, P: Phosphorus,
Ca: Calcium are the chemical symbol.
Fig. 6 Energy-dispersive X-ray spectroscopy (EDS) microanalysis
Quantification analysis at 5000X
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vitro toxicity and viability tests were aimed, and subse-
quent studies were planned to be carried out regarding
the animal experimentsand experiments to present the
biomechanical features.
Debates exist regarding the mechanical stability and
complication rates of the biocompatible materials but in
a recent study Bos and Smart et al. fixated the mandibu-
lar fractures with biocompatible materials and they
favoured their use due to their strenth and contributions
to bone remodelling [32, 33].
Design of novel orthopaedic bioimplants that resides
in body fluids and testing their biocompatibility have a
paramount importance in modern medicine. Biomate-
rials that lack the desired biological properties may not
be accepted as successful even if they carry the appropri-
ate physico-chemical properties
When polymeric implants are utilized, tissue – polymer
interaction should be taken into account. A number of in
vivo and in vitro studies dealing with these interacitons
were performed [34, 35].
In these researches, many molecules including but
limited to PEG-poly(ε-caprolactone) [36], HA, chito-
san, were used to avoid cellular toxicity in the host
[36–40]. For these reasons, in an in vitro setting, we
aimed to investigate the possible detrimental effects of
the ingredients of the bioimplant that could be ob-
served after application.
The ingredients of the designed bioimplant should have
certain properties. Physical, chemical and thermal proper-
ties of the designed biomaterial such as the expected
weight of the implant after application due to swelling ( %
hydration) and its attitude against the pH changes in
acidic, basic or neutral milleu should be well tested in vitro
before proceeding to animal or human studies [41].
After these studies were conducted and once the com-
ponents were proved to have no cytotoxic potential, then
Fig. 7 Bone cell viability (MTT assay; 540-nm absorbance) at 1., 7., 14., and 27. Days
Table 2 Expression rates of various antigens that obtained from flow cytometry by immunophenotyping and avarage fluorescent
density at primary cell culture
Antigens Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Exp M ± SD
HLA-DR 0 0 0 0 0 0 (−) 0
CD34 0 0 0 0 0 0 (−) 0
CD117 0 0 0 0 0 0 (−) 0
CD45 0 0 0 0 0 0 (−) 0
CD44 98.71 97.93 96.29 95.69 98.89 99.71 (+) %97.87 ± 1.57
(M: Mean & SD: Standard deviation. Exp: Expression)
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studies investigating its physico-chemical properties
such as the extent of change in the loss of elasticity and
friability.
The buffering capacity of the designed implant was
found to be superior to the controls in our study which
was represented by the changes measured in pH. This
difference was statistically significant (p < 0.05).
Bernstein et al. incubated bioresorbable implants
containing poly-L-lactide-co-glycolic acid/β-tricalcium-
phosphate (PLGA/TCP) (70 %/30 %) with human
osteoblast-like cells. They observed no associated cyto-
toxicity and witnessed more contact points under
ESEM in comparison to controls [35].
Bernstein et al., adhesion and proliferation of human
osteoblast-like cells on different biodegradable implant
materials used for graft fixation in ACL-reconstruction.
We used PLGA (85/15) in our experiment and our re-
sults were superior to control (PLGA with a ratio of 90/10)
in terms of cell viability and proliferation in MTT ELISA
and ESEM analysis.
Meyer et al. pointed out that the use of degredable
composite materails in orthopaedics is a significant issue
and they evaluated the effcts of PLGA degradation prod-
ucts on human osteoblasts in vitro. They concluded that
the toxicity of the polymer degradation products was
limited to only high concentrations [42].
In our study, in concordance with the existing literature,
the ingredients of the designed implant was not cytotoxic.
As a result, in the present study it was observed that
the PLGA-based prototype system biodegraded and the
samples showed a high buffering capacity. The design
was observed to possess the porosity and surface allow-
ing the cells to nest. Dense and shiny calcium zones
showed that the PLGA prototype contained more car-
bon atoms compared to the control group, which was an
indication of chemical stability. Moreover, it was note-
worthy to observe that the material also contained more
oxygen, which would boost the cell growth. One of most
important thing that, , the PLGA prototype has more ni-
trogen atom numbers, which was the proof of viability.
CD44, which is the symbol for osteopontin and hyaluro-
nan and also the indication of osteoblastic activity,
showed high and positive expression. The tests showed
that the new design is not toxic in vitro.
Conclusion
One of the criteria in the selection of implants for ortho-
pedic surgery is that a good implant should not need re-
moval and thus a second surgery. In the present study, a
bioabsorbable implant was designed considering this cri-
terion. The present study is the first step to prove the
safety of this new design by in vitro toxicity and viability
experiments.
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